Lacosamide

CHEMBL58323 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

250.3 g/mol

LogP

0.3

Phase

4

An anticonvulsant used as monotherapy or adjunctive treatment for focal seizures in adults and children with epilepsy. It works by enhancing the slow inactivation of sodium channels in neurons, reducing their ability to fire excessively.

Peso Molecular

250,2900 g/mol

LogP

0,30

TPSA

67,40 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Glaucoma Pain Management Rheumatoid Arthritis Epilepsy Migraine Schizophrenia Generalized Anxiety Disorder Oncology Stroke Chronic Pain

Mecanismo de Ação

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1

InChI

InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

Molecular Formula

C13H18N2O3

HBD / HBA

2 / 3

Ligações Rotacionáveis

6

Átomos Pesados

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An anticonvulsant used as monotherapy or adjunctive treatment for focal seizures in adults and children with epilepsy. It works by enhancing the slow inactivation of sodium channels in neurons, reducing their ability to fire excessively.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Lacosamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL58323. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 219078. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Lacosamide no PillFYI

Estrutura

Dados Rápidos

Fórmula: C13H18N2O3
Sinônimos: 3

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.